Identifying genetic factors that predict response to treatments for pulmonary arterial hypertension.
Genomic and Circulating Predictors of PAH response
This study is looking at how your genes and other factors in your body can help doctors figure out which treatments will work best for people with pulmonary arterial hypertension (PAH), so they can provide more personalized care and improve your health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11094927 on NIH RePORTER |
What this research studies
This research investigates how genetic and circulating factors can help predict which patients with pulmonary arterial hypertension (PAH) will respond to specific therapies. By utilizing advanced genetics and 'Omics' techniques, the study aims to identify biomarkers that can guide treatment decisions, potentially leading to better outcomes for patients. The research focuses on two main subsets of PAH patients: those who respond well to calcium channel blockers and those who benefit from prostacyclin therapy. The goal is to develop a precision medicine approach that tailors treatment based on individual genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pulmonary arterial hypertension who are seeking treatment options.
Not a fit: Patients with pulmonary arterial hypertension who are not interested in participating in genetic testing or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with pulmonary arterial hypertension.
How similar studies have performed: Previous research has shown promise in using genetic markers to predict treatment responses in similar conditions, indicating that this approach may be viable.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Hemnes, Anna R — Vanderbilt University Medical Center
- Study coordinator: Hemnes, Anna R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.